AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2487696 — intervention group
Group type: COMPARATOR
Intervention: No-rest group (n=36 joints)
Number of subjects: 30
Study 2487696 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups at later follow-up (average 10 months)
Number of subjects: 30
Study 344007 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (0.4 mg)
Number of subjects: 12
Study 344007 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (0.2 mg)
Number of subjects: 12
Study 344007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29913280 — intervention group
Group type: EXPERIMENTAL
Intervention: Emricasan (25 mg, twice daily for 3 months)
Number of subjects: 86
Study 29913280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 29393289 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 209
Study 29393289 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct lateral interbody fusion (DLIF)
Number of subjects: 209
Study 29393289 — intervention group
Group type: COMPARATOR
Intervention: Both TLIF and DLIF
Number of subjects: 209
Study 26331434 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (MT) combined with intravenous patient-controlled sufentanil analgesia
Number of subjects: 60
Study 26331434 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil alone (Control group)
Number of subjects: 60
Study 23215545 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek SupremeXT (FSXT)
Number of subjects: 54
Study 23215545 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric Evo Ceram (TEC)
Number of subjects: 54
Study 23215545 — intervention group
Group type: EXPERIMENTAL
Intervention: AELITE Aesthetic (AA)
Number of subjects: 54
Study 23215545 — intervention group
Group type: EXPERIMENTAL
Intervention: Estenia (E)
Number of subjects: 54
Study 23215545 — intervention group
Group type: EXPERIMENTAL
Intervention: Tescera ATL (TATL)
Number of subjects: 54
Study 20561672 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral via systematic identification through a brief mental health screening procedure
Number of subjects: 656
Study 20561672 — intervention group
Group type: COMPARATOR
Intervention: Usual process of identification by school personnel, parents, or students themselves
Number of subjects: 656
Study 19138370 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alprostadil cream (200 mcg initially, then 300 mcg or 100 mcg based on responsiveness)
Number of subjects: 1161
Study 19138370 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alprostadil cream (200 mcg initially, then adjusted)
Number of subjects: 1161
Study 19138370 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alprostadil cream
Number of subjects: 1161
Study 17006735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infiltration (Group B)
Number of subjects: 62
Study 17006735 — intervention group
Group type: COMPARATOR
Intervention: Sonographic gel application (Group A)
Number of subjects: 62
Study 17006735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 62
Study 15109503 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Number of subjects: 20
Study 15109503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11313669 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ifosfamide (10 g/m²), etoposide (900 mg/m²), and G-CSF (5 microg/kg twice a day) followed by autologous stem cell transplantation
Number of subjects: 44
Study 11313669 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ifosfamide (10 g/m²), mitoxantrone (20 mg/m²), and G-CSF (5 microg/kg) for patients with partial remission
Number of subjects: 44
Study 11313669 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation using BEAM conditioning for patients achieving complete remission
Number of subjects: 44
Study 11313669 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment regimen
Number of subjects: 44
Study 11313669 — intervention group
Group type: COMPARATOR
Intervention: Comparison with MINE-ESHAP salvage regimen
Number of subjects: 44
Study 9043455 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 0
Study 8180097 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips TL12 tubes (0.8 to 3.3 kJ/m2)
Number of subjects: 17
Study 8180097 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips TL01 tubes (3.1 to 18.6 kJ/m2)
Number of subjects: 17
Study 30149126 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 25
Study 30149126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 25943647 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 µg Folic Acid (FA) daily for a median of 23 days
Number of subjects: 58
Study 25943647 — intervention group
Group type: COMPARATOR
Intervention: B-complex (400 µg FA, 10 µg cyanocob(III)alamin, and 8 mg pyridoxine) daily for a median of 23 days
Number of subjects: 58
Study 25089513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Narrative Psychotherapy (CNP)
Number of subjects: 97
Study 25089513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Psychotherapy (CBP)
Number of subjects: 97
Study 23424889 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel + iron
Number of subjects: 406
Study 23424889 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel alone
Number of subjects: 406
Study 20451683 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3153
Study 20451683 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor
Number of subjects: 3153
Study 20451683 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anemia
Number of subjects: 3153
Study 19333040 — intervention group
Group type: EXPERIMENTAL
Intervention: Stoma group
Number of subjects: 34
Study 19333040 — intervention group
Group type: COMPARATOR
Intervention: Nonstoma group
Number of subjects: 34
Study 16205779 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 30
Study 16205779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15663559 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary egg exclusion during pregnancy and lactation
Number of subjects: 0
Study 15663559 — intervention group
Group type: COMPARATOR
Intervention: Unmodified healthy diet
Number of subjects: 0
Study 15663559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord OVA IgG concentration
Number of subjects: 0
Study 15663559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord IgG concentrations
Number of subjects: 0
Study 10791109 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-4 soluble receptor (IL-4sR)
Number of subjects: 60
Study 10791109 — intervention group
Group type: EXPERIMENTAL
Intervention: Other soluble cytokine receptors (IL-6sR, IL-1 beta, TNF-alpha, IL-1sR2, TNF-sR1, TNF-sR2)
Number of subjects: 60
Study 10791109 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 9340503 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase (10 MU in two bolus doses given 30 minutes apart)
Number of subjects: 15059
Study 9340503 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (up to 100 mg infused over a period of 90 minutes)
Number of subjects: 15059
Study 9340503 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 15059
Study 9340503 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 15059
Study 8322987 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (7 micrograms.kg‐1)
Number of subjects: 53
Study 8322987 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 53
Study 3089048 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 39
Study 3089048 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 39
Study 29527682 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-mediated intervention involving video modelling, therapist- and peer-mediation and free play over 10 sessions
Number of subjects: 10
Study 29527682 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study 29527682 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 10
Study 27543164 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Quit (mobile phone-based text message interventions)
Number of subjects: 2000
Study 27543164 — intervention group
Group type: COMPARATOR
Intervention: Control group (text messages unrelated to quitting)
Number of subjects: 2000
Study 23983272 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (cycle and strength training on 3 non-consecutive days per week for 12 weeks)
Number of subjects: 34
Study 23983272 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 34
Study 23983272 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 34
Study 22855277 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-exercise (MOD; 300 kcal/day)
Number of subjects: 61
Study 22855277 — intervention group
Group type: EXPERIMENTAL
Intervention: High-exercise (HIGH; 600 kcal/day)
Number of subjects: 61
Study 22855277 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 61
Study 20472116 — intervention group
Group type: EXPERIMENTAL
Intervention: celecoxib 400 mg orally
Number of subjects: 11
Study 20472116 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 18757090 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA 1 g daily
Number of subjects: 6975
Study 18757090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6975
Study 15777417 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 15
Study 15777417 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 15
Study 12003461 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet condition (anticipated food deprivation)
Number of subjects: 0
Study 12003461 — intervention group
Group type: COMPARATOR
Intervention: No-diet condition (control)
Number of subjects: 0
Study 10709595 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged operations
Number of subjects: 15
Study 7560238 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole impregnated collagen as a GTR membrane
Number of subjects: 16
Study 7560238 — intervention group
Group type: COMPARATOR
Intervention: Plain collagen barrier as control
Number of subjects: 16
Study 1950723 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuzpe method (ethinylestradiol 100 micrograms/levonorgestrel 500 micrograms repeated after 12 hours)
Number of subjects: 215
Study 1950723 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 600 mg repeated after 12 hours
Number of subjects: 215
Study 1950723 — intervention group
Group type: EXPERIMENTAL
Intervention: RU486 600 mg single dose
Number of subjects: 215
Study 7229228 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (6.5 +/- 0.9 mg/kg)
Number of subjects: 15
Study 7229228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30230041 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise
Number of subjects: 18
Study 30230041 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise
Number of subjects: 18
Study 28528804 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame group (n = 19)
Number of subjects: 38
Study 28528804 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 38
Study 26368562 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel preparation in LGIB patients
Number of subjects: 161
Study 26368562 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy in LGIB patients
Number of subjects: 161
Study 23418922 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid thoracoscopy (Olympus EndoEYE WA50120A, forceps)
Number of subjects: 84
Study 23418922 — intervention group
Group type: COMPARATOR
Intervention: Semi-rigid thoracoscopy (Olympus LTF-160, FB-55CR-1 forceps)
Number of subjects: 84
Study 20580779 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond diet
Number of subjects: 20
Study 19808459 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst antitachycardia pacing (ATP)
Number of subjects: 206
Study 19808459 — intervention group
Group type: COMPARATOR
Intervention: Ramp antitachycardia pacing (ATP)
Number of subjects: 206
Study 19808459 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ATP strategies
Number of subjects: 206
Study 17581288 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A (BTX-A) injections
Number of subjects: 0
Study 14979758 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of dependence and independence in causal inference (Experiment 1)
Number of subjects: 0
Study 14979758 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex patterns of conditional dependencies (Experiment 2)
Number of subjects: 0
Study 14979758 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence about patterns of dependence and independence (Experiment 3)
Number of subjects: 0
Study 14979758 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional probabilities (Experiments 4 and 5)
Number of subjects: 0
Study 12243664 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cryotherapy and triamcinolone
Number of subjects: 10
Study 12243664 — intervention group
Group type: COMPARATOR
Intervention: Intralesional corticosteroid alone
Number of subjects: 10
Study 12243664 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy alone
Number of subjects: 10
Study 9013304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal insemination (IPI)
Number of subjects: 205
Study 9013304 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI)
Number of subjects: 205
Study 8046781 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine hydrochloride (MH)
Number of subjects: 63
Study 8046781 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine hydrochloride retard
Number of subjects: 63
Study 2881414 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 13
Study 2881414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30249416 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS
Number of subjects: 22
Study 30249416 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 22
Study 28228424 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet soda containing sucralose
Number of subjects: 18
Study 28228424 — intervention group
Group type: COMPARATOR
Intervention: Carbonated water (control)
Number of subjects: 18
Study 25575743 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB)
Number of subjects: 40
Study 25575743 — intervention group
Group type: COMPARATOR
Intervention: Plain balloon angioplasty (BA)
Number of subjects: 40
Study 23102741 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA (tissue plasminogen activator)
Number of subjects: 624
Study 20423740 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine plus L-carnitine
Number of subjects: 254
Study 20423740 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine
Number of subjects: 254
Study 18692323 — intervention group
Group type: EXPERIMENTAL
Intervention: High mammographic breast density (MBD) (>/=75% density)
Number of subjects: 136
Study 18692323 — intervention group
Group type: EXPERIMENTAL
Intervention: MBD in the greatest quartile
Number of subjects: 136
Study 18692323 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (body mass index, >/=30 kg/m(2))
Number of subjects: 136
Study 17631452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac cell therapy using adult stem cells (muscular or bone marrow-derived)
Number of subjects: 0
Study 17631452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac cell therapy
Number of subjects: 0
Study 17631452 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryonic stem cells
Number of subjects: 0
Study 15153208 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (Group R, n = 10)
Number of subjects: 30
Study 15153208 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (Group B, n = 10)
Number of subjects: 30
Study 15153208 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine (Group L, n = 10)
Number of subjects: 30
Study 12161083 — intervention group
Group type: EXPERIMENTAL
Intervention: Different methods of multidimensional screening
Number of subjects: 30000
Study 9482768 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g maltitol in chocolate
Number of subjects: 20
Study 9482768 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g maltitol in chocolate
Number of subjects: 20
Study 8032307 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive oral hygiene care (INT)
Number of subjects: 150
Study 8032307 — intervention group
Group type: COMPARATOR
Intervention: Limited oral hygiene care (LIM)
Number of subjects: 150
Study 2686416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 200 mg intravenously every 12 hours
Number of subjects: 113
Study 2686416 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 2 g intravenously every eight hours
Number of subjects: 113
Study 31334795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group (n=581) - continuous intravenous insulin targeting blood glucose concentration of 80-130 mg/dL (4.4-7.2 mmol/L)
Number of subjects: 1151
Study 31334795 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group (n=570) - insulin on a sliding scale targeting blood glucose concentration of 80-179 mg/dL (4.4-9.9 mmol/L)
Number of subjects: 1151
Study 28911684 — intervention group
Group type: EXPERIMENTAL
Intervention: ANKASCIN 568 plus capsules (2 capsules daily for 12 weeks)
Number of subjects: 39
Study 28911684 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 2 capsules daily for 12 weeks)
Number of subjects: 39
Study 26315684 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER with ketoconazole
Number of subjects: 98
Study 26315684 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER with carbamazepine
Number of subjects: 98
Study 26315684 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER with alprazolam XR
Number of subjects: 98
Study 24429155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised magnesium sulphate (MgSO4) 2.5 mL (250 mmol/L; 151 mg per dose)
Number of subjects: 508
Study 24429155 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline) 2.5 mL
Number of subjects: 508
Study 20598640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypospadics
Number of subjects: 21
Study 20598640 — intervention group
Group type: COMPARATOR
Intervention: Normal infant boys
Number of subjects: 21
Study 19958427 — intervention group
Group type: EXPERIMENTAL
Intervention: LHA shampoo (0.1% lipohydroxy acid and 1.3% salicylic acid)
Number of subjects: 100
Study 19958427 — intervention group
Group type: COMPARATOR
Intervention: CPO shampoo (1.5% ciclopiroxolamine, 3% salicylic acid, and 0.5% menthol)
Number of subjects: 100
Study 17602064 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin 150 microg/week, doubled if hemoglobin did not increase by >1 g/dl after 4 weeks
Number of subjects: 196
Study 17602064 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin treatment
Number of subjects: 196
Study 17602064 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sTfR after 2 weeks and hemoglobin after 4 weeks
Number of subjects: 196
Study 14988450 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micro g FA capsule
Number of subjects: 13
Study 14988450 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micro g [6S]-5-MTHF capsule
Number of subjects: 13
Study 14988450 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 13
Study 11253418 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing of a humor video for 1 hour
Number of subjects: 52
Study 9490256 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 35
Study 9490256 — intervention group
Group type: COMPARATOR
Intervention: i.m. morphine
Number of subjects: 35
Study 7880151 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating 100g hilsa fish per day for 10 months
Number of subjects: 0
Study 7880151 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what they consumed)
Number of subjects: 0
Study 2500561 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with carbohydrate and fat emulsion (FAT group)
Number of subjects: 68
Study 2500561 — intervention group
Group type: COMPARATOR
Intervention: TPN with only carbohydrate (non‐FAT group)
Number of subjects: 68
Study 5540117 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0
Study 5540117 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 0
Study 5540117 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 5540117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31026118 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC predictors added to standard functional tumor volume MRI
Number of subjects: 415
Study 31026118 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC predictors for HR+/HER2-
Number of subjects: 415
Study 31026118 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC predictors for HR+/HER2+
Number of subjects: 415
Study 31026118 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC predictors for triple-negative breast cancer
Number of subjects: 415
Study 27771276 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque HD (plaque-identifying toothpaste)
Number of subjects: 61
Study 27771276 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 61
Study 25406267 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-only supervised exercise training for 12 weeks
Number of subjects: 35